Drug Profile
Research programme: analgesic therapeutics - Vernalis
Alternative Names: 1X 2000; 1X 3000; Analgesic therapeutics research programme - Vernalis; IX 4000Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Class Proteins
- Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain; Urinary incontinence
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 26 Jul 2005 Ionix Pharmaceuticals has been acquired and merged into Vernalis
- 29 Mar 2005 Preclinical trials in Urinary incontinence in United Kingdom (unspecified route)